111119-28-9 Usage
Uses
Gly-Arg-Gly-Asp-Ser-Pro-Lys (RGD peptide) has been used-as a blocking peptide to inhibit integrin-fibronectin bindingin adhesion assay performed on porcine trophectoderm to study the influence of TGFβ (transforming growth factor) on cell adhesionfor incubation of MC3T3-E1 osteoblast cells to determine its effect on cell adhesion measured by AFM (atomic force microscopy)for the preparation of RGD.Flt23k.NR nanoparticlesto determine the involvement of RGD-integrin bonding in cell adhesion process
General Description
Gly-Arg-Gly-Asp-Ser-Pro-Lys is a RGD peptide. Naturally occurring RGD peptides, present in the ECM (extracellalar matrix) proteins, are involved in facilitating integrin-mediated cell adhesion to matrix proteins. RGD peptide is present as repeats in cell-adhesion protein, such as fibronectin and vitronectin. This tripeptide is recognized by cells by specific integrins (e.g. β1 , β3 , and β5 subunits), present on the cell surface and associated with the actin filament via the FA (focal adhesion)-complex.
Biochem/physiol Actions
Fibronectin analog that binds to integrins.
Check Digit Verification of cas no
The CAS Registry Mumber 111119-28-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,1,1,1 and 9 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 111119-28:
(8*1)+(7*1)+(6*1)+(5*1)+(4*1)+(3*9)+(2*2)+(1*8)=69
69 % 10 = 9
So 111119-28-9 is a valid CAS Registry Number.
InChI:InChI=1/C28H49N11O11/c29-8-2-1-5-16(27(49)50)37-25(47)19-7-4-10-39(19)26(48)18(14-40)38-24(46)17(11-22(43)44)36-21(42)13-34-23(45)15(35-20(41)12-30)6-3-9-33-28(31)32/h15-19,40H,1-14,29-30H2,(H,34,45)(H,35,41)(H,36,42)(H,37,47)(H,38,46)(H,43,44)(H,49,50)(H4,31,32,33)/t15-,16-,17-,18-,19-/m0/s1
111119-28-9Relevant articles and documents
Fibrinogen-coated particles for therapeutic use
-
, (2008/06/13)
The invention provides a particle comprising fibrinogen bound on the surface of an albumin matrix, wherein said particle is capable of coaggregation with platelet, and of aggregation in a solution containing soluble fibrinogen at a concentration of soluble fibrinogen not capable by it self of formation of a clot upon activation by thrombin.
Non-crosslinked protein particles for therapeutic and diagnostic use
-
, (2008/06/13)
Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of hemoglobin in the particle composition. Particles which are primarily hemoglobin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against aggregation by the incorporation of either albumin, surface active agents or gelatin.
